Seminars in Hematology
Volume 44 , Pages S4-S16 , April 2007

Hypereosinophilic Syndrome and Molecularly Targeted Therapy

References 

  1. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference (The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations). Ann Intern Med. 1982;97:78–92
  2. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1–27
  3. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–2779
  4. Lefebvre C, Bletry O, Degoulet P, Guillevin L, Bentata-Pessayre M, Le Thi Huong D, et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann Med Interne (Paris). 1989;140:253–257
  5. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003;54:169–184
  6. Cools J. The hypereosinophilic syndrome: Idiopathic or not, that is the question. Haematologica. 2005;90:582–584
  7. Wilkins HJ, Crane MM, Copeland K, Williams WV. Hypereosinophilic syndrome: An update. Am J Hematol. 2005;80:148–157
  8. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660–4666
  9. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18:734–742
  10. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol. 2005;114:7–25
  11. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol. 1996;95:2–9
  12. Karnak D, Kayacan O, Beder S, Delibalta M. Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma. CMAJ. 2003;168:172–175
  13. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52:1–22
  14. Assa’ad AH, Spicer RL, Nelson DP, Zimmermann N, Rothenberg ME. Hypereosinophilic syndromes. Chem Immunol. 2000;76:208–229
  15. Bain BJ. Hypereosinophilia. Curr Opin Hematol. 2000;7:21–25
  16. Bain BJ. Eosinophilic leukemia and idiopathic hypereosinophilic syndrome are mutually exclusive diagnoses. Blood. 2004;104:3836;author reply 3836-3837
  17. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101–3109
  18. Roufosse F, Bartholomé E, Schandene L, Goldman M, Cogan E. The idiopathic hypereosinophilic syndrome: Clinical presentation, pathogenesis and therapeutic strategies. Drugs Today (Barc). 1998;34:361–373
  19. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology. 2005;72:287–292
  20. Weller PF, Monahan-Earley RA, Dvorak HF, Dvorak AM. Cytoplasmic lipid bodies of human eosinophils (Subcellular isolation and analysis of arachidonate incorporation). Am J Pathol. 1991;138:141–148
  21. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000;105:651–663
  22. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood. 2004;103:2879–2891
  23. Ascione L, De Michele M, Accadia M, Spadaro P, Rumolo S, Tuccillo B. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. Eur J Echocardiogr. 2004;5:386–390
  24. Stone RM, Gilliland DG, Klion AD. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin Oncol. 2004;31(suppl 6):12–17
  25. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167–172
  26. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102:109–114
  27. Epstein DM, Taormina V, Gefter WB, Miller WT. The hypereosinophilic syndrome. Radiology. 1981;140:59–62
  28. Hill R, Wang NS, Berry G. Hypereosinophilic syndrome with pulmonary vascular involvement. Angiology. 1984;35:238–244
  29. Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS. The cardiovascular manifestations of the hypereosinophilic syndrome (Prospective study of 26 patients, with review of the literature). Am J Med. 1979;67:572–582
  30. Leiferman KM, O’Duffy JD, Perry HO, Greipp PR, Giuliani ER, Gleich GJ. Recurrent incapacitating mucosal ulcerations (A prodrome of the hypereosinophilic syndrome). JAMA. 1982;247:1018–1020
  31. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol. 2006;117:1292–1302
  32. Klion AD. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology (Am Soc Hematol Educ Program). 2005;209–214
  33. Gotlib J, Cross NC, Gilliland DG. Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;19:535–569
  34. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005;114:26–40
  35. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol. 2006;133:468–492
  36. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: Still more heterogeneity. Curr Opin Immunol. 2005;17:679–684
  37. Sutton SA, Assa’ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol. 2005;115:51–60
  38. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol. 1996;92:176–183
  39. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol. 1998;58:137–141
  40. Luciano L, Catalano L, Sarrantonio C, Guerriero A, Califano C, Rotoli B. αIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica. 1999;84:651–653
  41. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: Report of a case and literature review. J Dermatol. 2000;27:110–115
  42. Baratta L, Afeltra A, Delfino M, De Castro S, Giorgino F, Rossi-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy—Case report and literature review. Angiology. 2002;53:465–470
  43. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol. 1991;62:230–231
  44. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103:2939–2941
  45. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113:115–119
  46. Anastasiadou E, Schwaller J. Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: An update. Curr Opin Hematol. 2003;10:40–48
  47. Hannah AL. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med. 2005;5:625–642
  48. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187
  49. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–104
  50. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–145
  51. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484–495
  52. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127–3132
  53. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566
  54. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440–2448
  55. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–894
  56. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet. 2001;358:1421–1423
  57. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  58. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38(suppl 5):S83–S87
  59. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710
  60. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689–695
  61. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214
  62. La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, et al. The hypereosinophilic syndrome: Fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica. 2005;90:596–601
  63. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038–3045
  64. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia. 2005;19:792–798
  65. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093–3096
  66. Robyn J, Lemery S, McCoy JP, Kubofcik J, Kim YJ, Pack S, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2006;132:286–292
  67. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood. 2006;107:4071–4079
  68. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473–478
  69. Martinelli G, Cilloni D, Rondoni M, Messa F, Ottaviani E, Gottardi E, et al. Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome (HES) (A phase II multicentric Italian clinical trial). Blood. 2005;106:113a;(abstr 375)
  70. Chung KF, Hew M, Score J, Jones AV, Reiter A, Cross NC, et al. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J. 2006;27:230–232
  71. Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, et al. The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol. 2006;76:535–536
  72. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia. 2005;19:286–287
  73. Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527–1535
  74. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. French Chronic Myeloid Leukemia Study Group Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223–229
  75. Druker BJ, Guilhot F, O’Brien S, Gathmann I, Kantarjian H, Gattermann N, et al. IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;335:2408–2417
  76. Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H, et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004;83:477–480
  77. Rose C, Dupire S, Roche-Lestienne C, Grardel N, Bourgeois E, Cambier N, et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia. 2004;18:354–355
  78. Cervetti G, Galimberti S, Carulli G, Petrini M. Imatinib therapy in hypereosinophilic syndrome: A case of molecular remission. Leuk Res. 2005;29:1097–1098
  79. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20:827–832
  80. Schaller JL, Burkland GA. Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med. 2001;3:9
  81. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881–884
  82. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–1578
  83. Gotlib J, Malone J, DeAngelo DJ, Stone RM, Gilliland DG, Clark J, et al. Imatinib mesylate (GLEEVEC™) induces rapid and complex hematologic remissions in patients with idiopathic hypereosinophilic syndrome (HES) without evidence of BCR-ABL or activating mutations in C-KIT and platelet-derived growth factor receptor-beta (PDGFR- β). Blood. 2002;100:798a;(abstr 3152)
  84. Nolasco I, Carvalho S, Parreira A. Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia. Blood. 2002;100:346b–347b(abstr 4940)
  85. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714–4716
  86. Ishii Y, Ito Y, Kuriyama Y, Tauchi T, Ohyashiki K. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. Leuk Res. 2004;28(suppl 1):79–80
  87. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 2003;115:587–589
  88. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27:739–742
  89. Salem Z, Zalloua PA, Chehal A, Bitar N, Abboud M, Kadri A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J. 2003;4:410–412
  90. Malagola M, Martinelli G, Rondoni M, Ottaviani E, Piccaluga PP, Ricci P, et al. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: Imatinib mesylate may induce complete molecular and imaging remission. Haematologica. 2004;89:ECR25
  91. Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopathic hypereosinophilic syndrome. Haematologica. 2004;89:236–237
  92. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM, et al. Heterogeneity of response to imatinib-mesylate (Glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis. Leuk Lymphoma. 2004;45:1219–1222
  93. Payne SM, Kovacs MJ. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome. Ann Pharmacother. 2004;38:1215–1218
  94. Pottier P, Planchon B, Grossi O. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha]. Rev Med Interne. 2003;24:542–546
  95. Rotoli B, Catalano L, Galderisi M, Luciano L, Pollio G, Guerriero A, et al. Rapid reversion of Loeffler’s endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma. 2004;45:2503–2507
  96. Smith KJ, Jacobson E, Hamza S, Skelton H. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses. Arch Dermatol. 2004;140:584–588
  97. Tan D, Hwang W, Ng HJ, Goh YT, Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: A case report. Int J Hematol. 2004;80:75–77
  98. Wolf D, Gastl G, Rumpold H. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Dtsch Med Wochenschr. 2004;129:2104–2106
  99. Anghel G, De Rosa L, Ruscio C, Petti N, Riccardi M, Severino A, et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori. 2005;91:67–70
  100. Imashuku S, Kakazu N, Ueda I, Morimoto A, Harada H, Teramura T, et al. Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations. Int J Hematol. 2005;81:310–314
  101. Müller AM, Martens UM, Hofmann SC, Bruckner-Tuderman L, Mertelsmann R, Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: Two case reports and a comprehensive review of the literature. Ann Hematol. 2006;85:1–16
  102. Musial J, Brzezinska-Kolarz B, Sanak M, Szczeklik A. Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib. Eur J Haematol. 2005;75:87–88
  103. Onitilo AA, Kio EA, Singh AK, Lazarchick J. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Leuk Lymphoma. 2005;46:1667–1670

PII: S0037-1963(07)00023-6

doi: 10.1053/j.seminhematol.2007.02.002

Seminars in Hematology
Volume 44 , Pages S4-S16 , April 2007

Article Tools

* Image Usage & Resolution